| Authors: |
Coukos G; University Hospital of Lausanne, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland., Donia M; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Gastman BR; Iovance Biotherapeutics, San Carlos, California, USA., Goff SL; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Gros A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Harari A; University Hospital of Lausanne, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland., Hernandez S; University of California San Francisco, San Francisco, California, USA., Ito F; University of Southern California, Los Angeles, California, USA., Maker AV; University of California San Francisco, San Francisco, California, USA., Mullinax JE; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA., Murthy P; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Pai SI; Yale University School of Medicine, New Haven, Connecticut, USA., Prabhakaran S; University of New Mexico, UNM Comprehensive Cancer Center, Albuquerque, New Mexico, USA., Restifo NP; Medici Therapeutics, Boston, Massachusetts, USA., Silver NL; Cleveland Clinic, Cleveland, Ohio, USA., Marincola Smith P; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Turcotte S; Centre Hospitalier de l'Université de Montréal, Montreal, Québec, Canada., Wagner PL; Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA., Yang JC; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Lotze MT; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA lotzemt@upmc.edu. |
